Peptide Inhibitors of Protein-Protein Interactions: Research Breakthroughs

Protein-protein interactions (PPIs) control nearly every important biological process in a living cell. Signaling cascades, gene regulation, immune responses, and cell death all depend on specific proteins binding to each other in precise ways. When those interactions go wrong, disease follows. For decades, targeting PPIs with drugs seemed almost impossible. Peptides are changing that.

This post covers the most significant research advances in peptide-based PPI inhibitors, from the foundational chemistry that makes them possible to the clinical programs that are putting this science to work against real diseases.

Why Protein-Protein Interactions Are Hard Drug Targets

Traditional small molecule drugs work best against proteins with well-defined binding pockets: enzymes with active sites, receptors with ligand-binding domains, ion channels with gating mechanisms. These pocket-like structures can fit a small, rigid molecule that blocks function.

PPIs are different. The surfaces where two proteins contact each other tend to be large, flat, and featureless. A typical PPI interface covers 750 to 1500 square angstroms of surface area. Small molecules, which typically contact less than 300 square angstroms, simply do not have enough surface contact to compete effectively.

Peptides are better suited to this challenge. They can be designed to mimic the surface of one protein partner, presenting the same amino acid residues in the same spatial arrangement, which allows them to occupy the interface and block the other protein from binding.

More than 650,000 protein-protein interactions have been identified in the human interactome, yet fewer than 2% of these have been successfully targeted by an approved drug. Peptide inhibitors are a leading strategy for expanding into this vast untapped space.

The Core Chemistry: What Makes a Good PPI Peptide

Mimicking Protein Secondary Structure

Most PPI interactions are mediated by defined secondary structure elements in one or both protein partners. Alpha helices, beta hairpins, and loop regions are the most common structural features that drive PPI binding.

An effective PPI peptide must mimic these structural features accurately. The problem is that short peptides taken out of their protein context are often structurally disordered. Without the support of the folded protein around them, they lose the defined shape that made them effective binders.

This is why constrained peptides have become so important in PPI inhibitor research. By introducing molecular constraints that force the peptide into the bioactive conformation, researchers can restore the binding affinity that is lost when a sequence is extracted from its protein context.

Stapled Peptides

Stapled peptides are one of the most studied approaches to constraining peptide structure for PPI inhibition. The "staple" is a hydrocarbon crosslink, typically formed by joining two modified amino acids with a ring-closing metathesis reaction. This crosslink holds the peptide in an alpha-helical conformation.

The helix stabilization achieved by stapling has several benefits beyond just binding affinity. Stapled peptides tend to be more resistant to proteolytic degradation, which extends their in vivo half-life. Some stapled peptides can cross cell membranes, which is essential for targeting intracellular PPIs. And the stabilized helix presents a more defined binding surface to the target protein.

Work from the groups of Loren Walensky at Dana-Farber Cancer Institute and Gregory Verdine at Harvard has been particularly influential in demonstrating the therapeutic potential of stapled peptides against cancer-relevant targets. Walensky's work on stapled BH3 peptides targeting the BCL-2 family of anti-apoptotic proteins helped establish the scientific foundation for the field.

Cyclic Peptides

Cyclic peptides are another major approach to constraining peptide structure. Cyclization can be achieved through a backbone-to-backbone bond, a disulfide bridge between cysteine residues, a head-to-tail amide bond, or other chemical linkages.

Cyclization reduces the conformational flexibility of the peptide, which improves binding affinity by reducing the entropic cost of binding. Cyclic peptides also tend to have better metabolic stability than linear peptides because they present fewer sites for proteolytic cleavage.

Natural cyclic peptides like cyclosporin A demonstrated decades ago that cyclic peptide scaffolds can achieve drug-like properties including oral bioavailability in some cases. Modern synthetic biology approaches, including DNA-encoded cyclic peptide libraries and ribosomal display methods like mRNA display, have made it possible to screen billions of cyclic peptide sequences against any PPI target.

Beta-Sheet Mimetics and Turn Peptides

Not all PPI interfaces are mediated by helices. Beta-sheet and beta-turn structures are also important binding elements. Designing peptides that adopt these conformations is more challenging than helix stabilization, but significant progress has been made.

Beta-hairpin cyclic peptides, in which a short cyclic peptide is designed to fold into a beta-hairpin conformation, have shown promise against several PPI targets. Loop-mimetic peptides that capture the structure of surface-exposed loops are also an active area of research.

Key Therapeutic Targets and Recent Breakthroughs

MDM2-p53

The interaction between the MDM2 protein and the tumor suppressor p53 is one of the most studied PPI targets in oncology. MDM2 binds to p53 and targets it for degradation, effectively silencing the cell's most important anti-cancer mechanism. In many human cancers, MDM2 is overexpressed, and disrupting the MDM2-p53 interaction could restore p53 activity and trigger cancer cell death.

Several stapled peptide programs targeting MDM2-p53 have progressed through preclinical development, and some have entered early clinical trials. The challenge has been achieving the balance of potency, selectivity, and tolerability required for clinical success. Recent reports of improved stapled peptide designs with better cell penetration and more favorable pharmacokinetics suggest that clinical progress is on the horizon.

BCL-2 Family and Apoptosis

The BCL-2 family of proteins controls mitochondrial apoptosis. Pro-apoptotic members like BAX and BAK are kept in check by anti-apoptotic members like BCL-2, BCL-XL, and MCL-1. In cancer cells, overexpression of anti-apoptotic BCL-2 family members allows them to evade the apoptotic signals that would normally cause cell death.

BH3 domain peptides, which mimic the natural binding interface used by pro-apoptotic proteins, were among the first PPI peptides studied as potential cancer therapeutics. The development of ABT-737 and ultimately venetoclax, a small molecule BH3 mimetic, validated the target clinically. Research on stapled BH3 peptides continues to explore whether peptide-based approaches can target BCL-2 family members like MCL-1 that have been difficult to address with small molecules.

RAS-Effector Interactions

Mutant RAS proteins are among the most common oncogenes in human cancer. RAS drives tumor growth by inappropriately activating downstream signaling through its interactions with effector proteins. For decades, RAS was considered "undruggable" because the interaction surface between RAS and its effectors lacks the obvious binding pocket required for small molecule inhibition.

Cyclic peptide approaches have shown surprising promise against some RAS-effector interactions. Researchers have identified cyclic peptides that bind to the effector-binding surface of RAS and block downstream signaling. While the clinical translation of these findings is still in early stages, the ability to demonstrate RAS surface binding with a peptide scaffold represents a significant conceptual advance.

A 2024 paper published in Nature Chemical Biology reported the discovery of cyclic peptides that selectively inhibit the KRAS-SOS1 interaction in cells with low nanomolar potency, a result that was not considered achievable with peptide scaffolds just a few years earlier.

Transcription Factor Interactions

Transcription factors control gene expression and are frequently dysregulated in cancer and other diseases. They are attractive drug targets but have historically been considered undruggable because they lack enzymatic active sites and their DNA-binding and protein-protein interaction surfaces are large and featureless.

Peptide inhibitors of transcription factor PPIs have made progress on several fronts. The MYC-MAX interaction, which drives MYC oncogene activity in many cancers, has been targeted with both linear and cyclic peptides. The YAP-TEAD interaction, a key node in the Hippo pathway, has also been successfully disrupted with peptide and peptidomimetic approaches.

These advances are especially significant because transcription factor targets represent a vast space of disease-relevant biology that has been largely inaccessible to conventional drugs.

Overcoming the Delivery Challenge

The biggest remaining obstacle for intracellular PPI inhibitors is getting the peptide inside the cell. Most therapeutic targets of interest are inside cells, not on the cell surface.

Several strategies are being actively pursued to solve this problem.

Cell-penetrating peptides (CPPs), which include sequences like TAT from HIV and polyarginine, can help carry cargo across cell membranes. When fused to PPI inhibitor peptides, CPPs can facilitate intracellular delivery, though the efficiency and selectivity of delivery remain areas of active research.

Lipid nanoparticles (LNPs), the same delivery technology used in mRNA vaccines, have been adapted for peptide delivery. LNP-encapsulated peptides can be efficiently taken up by cells and released into the cytoplasm, providing a potentially generalizable delivery solution.

Endosomal escape peptides, which help peptides escape from the cellular compartment they are trapped in after uptake, are another area of active development. The challenge is that most internalized molecules end up degraded in lysosomes rather than released into the cytoplasm where they need to go.

The Role of Computational Design

Computational methods have accelerated progress in PPI peptide design significantly. Structure-based design, using crystal structures of PPI interfaces to guide peptide design, allows researchers to understand exactly which residues are most important for binding and which modifications are likely to improve affinity.

AlphaFold and related protein structure prediction tools have made it possible to design PPI inhibitor peptides against targets whose structures were not previously known. This dramatically expands the number of PPIs that can be rationally targeted.

Machine learning approaches are also being applied to optimize peptide sequences for binding affinity, protease resistance, and cell permeability simultaneously. The ability to computationally screen millions of peptide variants before synthesizing any of them is transforming the speed and efficiency of peptide drug discovery.

For anyone interested in careers at the intersection of peptide science and computational biology, this area represents one of the fastest-growing and most exciting opportunities in the field. For more information on career opportunities in this expanding area, see our guide on essential skills for peptide project managers in biotech, which discusses how interdisciplinary roles are evolving.

Regulatory and Development Considerations

PPI peptides face some unique challenges in drug development. Demonstrating that a peptide is truly acting through PPI inhibition, rather than through non-specific effects, requires careful mechanistic studies. Designing these studies appropriately is an important part of building a convincing regulatory package.

The analytical characterization of PPI inhibitors is also more complex than for conventional drugs. Showing that the peptide adopts the intended conformation in solution, that it binds the target with the expected affinity, and that it disrupts the PPI interaction in cells all require specialized biophysical methods.

Scientists who understand both peptide chemistry and biophysical characterization methods like surface plasmon resonance, isothermal titration calorimetry, and NMR are particularly valuable contributors to PPI peptide programs.

According to the National Cancer Institute's drug discovery resources, protein-protein interaction inhibitors represent one of the most active areas of targeted cancer therapy research, with substantial NCI funding supporting both academic and translational research in this area.

FAQs

What is a protein-protein interaction inhibitor? A PPI inhibitor is a molecule, in this case a peptide, that blocks two proteins from binding to each other. Most biological processes rely on proteins interacting, and when the wrong interactions occur in disease, blocking them can restore normal function or kill diseased cells.

Why are peptides particularly useful for targeting PPIs compared to small molecules? Peptides can cover the large, flat binding surfaces that characterize most PPI interfaces. Small molecules are too small to make sufficient contact with these surfaces to compete effectively. Peptides can be designed to mimic the shape of one protein's binding surface, allowing them to compete for the other protein's binding site.

What is a stapled peptide and how does the stapling work? A stapled peptide contains a chemical crosslink between two amino acid side chains that forces the peptide into a helical conformation. The staple is typically formed using ring-closing metathesis chemistry on two modified amino acids incorporated at specific positions in the sequence. The crosslink holds the helix rigid and improves cell permeability and metabolic stability.

Are any PPI peptide drugs currently approved? Several approved drugs have PPI inhibitor mechanisms, though most early PPI drugs were natural products or their derivatives rather than rationally designed synthetic peptides. The cyclic peptide class has the strongest track record in the clinic so far, with oral cyclic peptides under investigation for several targets in advanced clinical trials.

What careers are available in the PPI peptide research space? Opportunities exist for synthetic peptide chemists, structural biologists, computational chemists, biochemists, cell biologists, and pharmacologists. Many of the most impactful roles sit at the intersection of these disciplines, and scientists who can work across traditional department boundaries are particularly valued in this field.